Evidence map›Paper›PMID 41522186›Full record

ArticleEuropean clinical respiratory journal2026

Lung abscess as an adverse effect of Risankizumab.

Zarif Kazi, Stuart Jesin, Samir Ghimire, Toni-Ann Lewis, Thai Donenfeld, Kevin Clements, William Pascal

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in European clinical respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zarif KaziInternal Medicine, Department of Medicine, Maimonides Medical Center, Brooklyn, NY, USA.ORCID https://orcid.org/0009-0008-1491-6972
Stuart JesinInternal Medicine, Department of Medicine, Maimonides Medical Center, Brooklyn, NY, USA.
Samir GhimireInternal Medicine, Department of Medicine, Maimonides Medical Center, Brooklyn, NY, USA.
Toni-Ann LewisInternal Medicine, Department of Medicine, Maimonides Medical Center, Brooklyn, NY, USA.
Thai DonenfeldPulmonary and Critical Care, Department of Medicine, Maimonides Medical Center, Brooklyn, NY, USA.
Kevin ClementsPulmonary and Critical Care, Department of Medicine, Maimonides Medical Center, Brooklyn, NY, USA.
William PascalPulmonary and Critical Care, Department of Medicine, Maimonides Medical Center, Brooklyn, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Risankizumab is used for prolongated duration by patients, necessitating further research to characterize the infectious risks involved. Case Presentation: A 30-year-old man on Risankizumab for psoriasis and alopecia presented with pleuritic chest pain, cough, hemoptysis, fever, and myalgias. Initial computed tomography (CT) scan showed a 4.9 × 7.7 × 6.1 cm irregular cavitary lesion in the medial right lower lobe with thickened walls and surrounding ground-glass opacification. Tuberculosis was ruled out with 3 negative acid-fast bacilli (AFB) samples and 2 negative samples for Conclusion: Given the lack of notable risk factors for lung abscess, this case suggests a possible association with Risankizumab, which may have contributed to immunosuppression.

Indexed as

infectionLung abscessMRSAMycobacterium aviumpulmonaryRisankizumabSkyrizi

Identifiers

PMID41522186
PMCPMC12781944

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.